Talquetamab clinical trials
Also written JNJ-64407564 and Talvey.
How each study uses talquetamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the talquetamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Aug 2023 · TALVEY · BLA 761342 (FDA, Drugs@FDA)
- European Union
- 21 Aug 2023 · Talvey · EMEA/H/C/005864 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2025 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 20
Janssen Research & Development, LLC (11) · PETHEMA Foundation (1) · Janssen Pharmaceutical K.K. (1) · Alliance for Clinical Trials in Oncology (1) · University of Arkansas (1) · Polish Myeloma Consortium (1) · Montefiore Medical Center (1) · First Affiliated Hospital of Chongqing Medical University (1)
Often tested with
Tested in the same studies.
Teclistamab (14) · Lenalidomide (4) · Dexamethasone (3) · Pomalidomide (2) · Ciltacabtagene autoleucel (2) · Daratumumab (2) · Bortezomib (2) · Ramantamig (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11, 1 in phase 3
Studies that test talquetamab, phase 3 first.
- Jul 2027A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentPhase 3 · Janssen Research & Development, LLC
- Nov 2026Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsPhase 2 · North Estonia Medical Centre
- Jan 2027Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapsePhase 2 · Larysa Sanchez
- Mar 2027Talquetamab in Patients With Refractory Generalized Myasthenia GravisNot applicable · First Affiliated Hospital of Chongqing Medical University
- Jun 2027A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 2 · Janssen Research & Development, LLC
- Jul 2027Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaPhase 1 · Massachusetts General Hospital
- Jul 2027Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaPhase 1 · Medical College of Wisconsin
- Jul 2027Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaPhase 1 · Alfred Chung, MD
- Aug 2027Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaPhase 2 · SCRI Development Innovations, LLC
- Aug 2027A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaPhase 2 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses talquetamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingPhase 3University of LeedsNCT07649525Written as TalquetamabHow we know
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as TalquetamabHow we know
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 2Janssen Research & Development, LLCNCT04634552Written as TalquetamabHow we know
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as TalquetamabHow we know
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingPhase 2Naresh BummaNCT07657312Written as TalquetamabHow we know
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingPhase 2Janssen Research & Development, LLCNCT06500884Written as TalquetamabHow we know
- Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseRecruitingPhase 2Larysa SanchezNCT06827860Written as TalquetamabHow we know
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple MyelomaNot yet recruitingPhase 2University of ArkansasNCT07029776Written as teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenanceHow we know
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as TalquetamabHow we know
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingPhase 1Montefiore Medical CenterNCT07720843Written as TalquetamabHow we know
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingPhase 2Stanford UniversityNCT06461988Written as TalquetamabHow we know
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingPhase 2SCRI Development Innovations, LLCNCT05972135Written as TalquetamabHow we know
- Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.RecruitingPhase 2European Myeloma Network B.V.NCT07107529Written as TalquetamabHow we know
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingPhase 1Massachusetts General HospitalNCT07032714Written as TalquetamabHow we know
- Talquetamab in Patients With Refractory Generalized Myasthenia GravisNot yet recruitingNot applicableFirst Affiliated Hospital of Chongqing Medical UniversityNCT07499323Written as TalquetamabHow we know
- Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Alfred Chung, MDNCT06348108Written as TalquetamabHow we know
- A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell TherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06066346Written as TalquetamabHow we know
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)RecruitingPhase 2Carl Ola Landgren, MD, PhDNCT06100237Written as TalquetamabHow we know
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1Medical College of WisconsinNCT07093554Written as TalquetamabHow we know
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingPhase 2University of Heidelberg Medical CenterNCT05695508Written as TalquetamabHow we know
See all 32 studies that test talquetamab →
Given beside what is tested · 6 — talquetamab is usual care or a partner of the new treatment
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingPhase 2Noffar BarNCT06993675Written as TalquetamabHow we know
- Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingPhase 1Christopher StrouseNCT07581704Written as TalquetambHow we know
- A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04108195Written as TalquetamabHow we know
- A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT05050097Written as TalquetamabHow we know
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Nantes University HospitalNCT06353022Written as TalquetamabHow we know
- An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedPhase 2CelgeneNCT03601078Written as TalquetamabHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call talquetamab · ClinicalTrials.gg INT002094
- MeSH (NLM) C000730985talquetamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4W3KFI3TN3TALQUETAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q116777032talquetamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171840TalquetamabOne source FDA
- DrugBank DB16678One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730985 | talquetamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4W3KFI3TN3 | TALQUETAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q116777032 | talquetamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171840 | Talquetamab | One source FDA |
| DrugBank | DB16678 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.